Tag: AVEO,EGFR TKI therapy,ESMO,Ficlatuzumab,NSCLC,Non-Small Cell Lung Cancer,Press Releases,Veristrat,blood-based cancer test,cancer diagnostics,gefitinib,liquid biopsy,lung cancer,oncology
-
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab
AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the presentation of results from a retrospective exploratory analysis using VeriStrat®, a commercially available serum protein test, to identify patients most likely to benefit from the addition of ficlatuzumab, AVEO’s HGF inhibitory antibody, to epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy in a…